Tvardi Therapeutics Inc. (TVRD)
NASDAQ: TVRD
· Real-Time Price · USD
24.44
0.44 (1.83%)
At close: Aug 18, 2025, 3:59 PM
24.74
1.23%
After-hours: Aug 18, 2025, 04:10 PM EDT
1.83% (1D)
| Bid | 22.3 |
| Market Cap | 228.78M |
| Revenue (ttm) | 7.57M |
| Net Income (ttm) | -45.08M |
| EPS (ttm) | -2.25 |
| PE Ratio (ttm) | -10.86 |
| Forward PE | -7.74 |
| Analyst | Buy |
| Ask | 26 |
| Volume | 8,808 |
| Avg. Volume (20D) | 58,703 |
| Open | 24.00 |
| Previous Close | 24.00 |
| Day's Range | 23.79 - 25.13 |
| 52-Week Range | 8.14 - 34.31 |
| Beta | 0.21 |
About TVRD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TVRD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TVRD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+9.07%
Tvardi Therapeutics shares are trading higher afte...
Unlock content with
Pro Subscription
2 months ago
+14.78%
Tvardi Therapeutics shares are trading higher after the company announced it completed the enrollment for its phase 2 clinical trial of TTI-101.
3 months ago · businesswire.com
Tvardi Therapeutics to Participate in Upcoming Investor ConferencesHOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...